Affiliation:
1. Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK
2. Organon R&D Finland, Itäinen Pitkäkatu 4, 20520 Turku, Finland
Abstract
One aspect of reproducibility in preclinical research that is frequently overlooked is the physical condition in which physiological, pharmacological, or behavioural recordings are conducted. In this study, the physical conditions of mice were altered through the attachments of wireless electrophysiological recording devices (Neural Activity Tracker-1, NAT-1). NAT-1 devices are miniaturised multichannel devices with onboard memory for direct high-resolution recording of brain activity for >48 h. Such devices may limit the mobility of animals and affect their behavioural performance due to the added weight (total weight of approximately 3.4 g). The mice were additionally treated with saline (control), N-methyl-D-aspartate (NMDA) receptor antagonist MK801 (0.85 mg/kg), or the muscarinic acetylcholine receptor blocker scopolamine (0.65 mg/kg) to allow exploration of the effect of NAT-1 attachments in pharmacologically treated mice. We found only minimal differences in behavioural outcomes with NAT-1 attachments in standard parameters of locomotor activity widely reported for the open field test between the drug treatments. Hypoactivity was globally observed as a consistent outcome in the MK801-treated mice and hyperactivity in scopolamine groups regardless of NAT-1 attachments. These data collectively confirm the reproducibility for combined behavioural, pharmacological, and physiological endpoints even in the presence of lightweight wireless data loggers. The NAT-1 therefore constitutes a pertinent tool for investigating brain activity in, e.g., drug discovery and models of neuropsychiatric and/or neurodegenerative diseases with minimal effects on pharmacological and behavioural outcomes.
Funder
Innovative Medicines Initiative
Reference50 articles.
1. Cortical EEG Oscillations and Network Connectivity as Efficacy Indices for Assessing Drugs with Cognition Enhancing Potential;Ahnaou;Neuropharmacology,2014
2. Crispin-Bailey, C., Moulds, A., Platt, B., Hollier, G.P., Freeman, M.J., and Fargus, A.G. (2013, January 25–29). A Miniaturized 4-Channel, 2KSa/Sec Biosignal Data Recorder With 3-Axis Accelerometer and Infra-Red Timestamp Function. Proceedings of the Seventh International Conference on Sensor Technologies and Applications, Porto, Portugal.
3. Of Mice and Motion: Behavioural-EEG Phenotyping of Alzheimer’s Disease Mouse Models;Crouch;J. Neurosci. Methods,2019
4. Replicable in Vivo Physiological and Behavioral Phenotypes of the Shank3B Null Mutant Mouse Model of Autism;Dhamne;Mol. Autism,2017
5. Pharmaco-EEG Studies in Animals: An Overview of Contemporary Translational Applications;Drinkenburg;Neuropsychobiology,2015